TSUTOMU NAGATA,MASAHIRO INOUE,YUKA ASHIDA,KENGO NOGUCHI,MAKOTO ONO
申请号：
SG2012055893
公开号：
SG182767A1
申请日:
2011.03.14
申请国别(地区):
SG
年份:
2012
代理人:
摘要：
AbstractA compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a Cl to 06 alkyl group, etc； RI, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a Cl to C6 alkyl group； R4 represents a hydrogen atom or a prodrug group； and Y represents -CH2-CHR5-CH2-NHR6 (wherein R5 represents a hydrogen atom, a Cl to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.
